Comparative Pharmacology
Head-to-head clinical analysis: FENOPROFEN CALCIUM versus NAPROXEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOPROFEN CALCIUM versus NAPROXEN SODIUM.
FENOPROFEN CALCIUM vs NAPROXEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Oral: 300-600 mg every 6-8 hours as needed; maximum 3200 mg/day.
220-550 mg orally twice daily; maximum 1375 mg/day.
None Documented
None Documented
Terminal elimination half-life is 2–3 hours; may be prolonged in elderly and patients with hepatic impairment.
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Primarily renal; approximately 90% of a dose is excreted in urine as glucuronide conjugates and unchanged drug; <2% excreted in feces.
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Category C
Category D/X
NSAID
NSAID